Obesity treatment with a satiety promoting peptide
Paul David Berk, M.D.
This peptide is a natural hormone peptide. Already has natural biological activity in the gut and in significantly under-expressed in obese patients. Successfully reduces body weight by reducing food intake, eliminating adipocyte free fatty acid uptake rates in several models of obesity, including tissue samples from obese humans.Patent information:(WO2012051567)Tech Ventures Reference: IR 2723
Treatment of obesity, general weight control and appetite regulationTreatment of metabolic syndrome, insulin resistance, fatty liver disease, obesity related cardiomyopathy and other obesity-associated disorders. Detection of obesity or obesity-associated disordersDetection of an obesity classification based on message or protein expression profilingAn alternative treatment and/or complement to obesity surgery
Paul David Berk, M.D.
美国
